These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2884198)

  • 1. Anti-carcinogenic effects of a serine protease inhibitor (FOY-305) through the suppression of neutral serine protease activity during chemical hepatocarcinogenesis in rats.
    Yamauchi Y; Kobayashi M; Watanabe A
    Hiroshima J Med Sci; 1987 Mar; 36(1):81-7. PubMed ID: 2884198
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inhibitory effect of FOY-305 on liver metastasis of the pancreatic cancer].
    Ohta T; Futagami F; Arakawa H; Tsukioka Y; Kitagawa H; Kayahara M; Nagakawa T; Miyazaki I
    Gan To Kagaku Ryoho; 1996 Oct; 23(12):1669-72. PubMed ID: 8886041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effects of FOY on lysosomes in hemorrhagic hypotension--a histological analysis].
    Miyawaki T; Sameshima T; Miyao J; Oda T
    Masui; 1984 Mar; 33(3):263-8. PubMed ID: 6429387
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of serine protease inhibitor FOY-305 and heparin on the growth of squamous cell carcinoma.
    Ohkoshi M; Akagawa T; Nakajima M
    Anticancer Res; 1993; 13(4):963-6. PubMed ID: 8352567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of FOY-305 on the activity and secretion of pancreatic enzymes in vitro].
    Stöckmann F; Göke B; Otto J; Lankisch PG; Creutzfeldt W
    Z Gastroenterol; 1984 Jun; 22(6):311-7. PubMed ID: 6205521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibitors of serine proteinase inhibit epidermal cell migration (epiboly)].
    Chen DL; Nakajima S; Morioka S; Ogawa H
    Nihon Hifuka Gakkai Zasshi; 1988 Apr; 98(5):571-4. PubMed ID: 3241433
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of a small molecular weight proteinase inhibitor, gabexate mesilate (FOY), on insulin receptor function in vitro.
    Göke R; Göke B; Steinfelder HJ; Arnold R
    Int J Pancreatol; 1988 Mar; 3(2-3):135-42. PubMed ID: 3129526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the synthetic protease inhibitor [N,N-dimethylcarbamoyl-methyl 4-(4-guanidinobenzoyloxy)-phenylacetate] methanesulfate on carcinogenesis by 3-methylcholanthrene in mouse skin.
    Ohkoshi M; Fujii S
    J Natl Cancer Inst; 1983 Nov; 71(5):1053-7. PubMed ID: 6580482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-invasive activity of synthetic serine protease inhibitors and its combined effect with a matrix metalloproteinase inhibitor.
    Ikeda T; Murakami K; Hayakawa Y; Fujii H; Ohkoshi M; Saiki I
    Anticancer Res; 1998; 18(6A):4259-65. PubMed ID: 9891476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Protease inhibitors as anticancer chemotherapy--experimental and clinical studies].
    Ohkoshi M
    Gan To Kagaku Ryoho; 1995 Mar; 22(4):417-30. PubMed ID: 7887633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparative systemic analysis of experimental models of chemical hepatic carcinogenesis in the rat].
    Lans M; de Gerlache J; Préat V; Taper H; Roberfroid M
    C R Seances Soc Biol Fil; 1984; 178(4):397-407. PubMed ID: 6151868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the serine protease inhibitors FOY and FOY 305 on phospholipase A1 (EC 3.1.1.32) activity in rat - liver lysosomes.
    Kunze H; Bohn E
    Pharmacol Res Commun; 1983 May; 15(5):451-9. PubMed ID: 6412250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. General and selective inhibition of pancreatic enzyme discharge using a proteinase inhibitor (FOY-305).
    Adler G; Rausch U; Weidenbach F; Arnold R; Kern HF
    Klin Wochenschr; 1984 May; 62(9):406-11. PubMed ID: 6202931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous administration of the synthetic trypsin inhibitor Foy-305 induces hypertrophy of the exocrine pancreas.
    Wereszczyńska-Siemiatkowska U; Pohl U; Otto J; Lankisch PG
    Digestion; 1987; 37(3):144-8. PubMed ID: 2443410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FOY: [ethyl p-(6-guanidinohexanoyloxy) benzoate] methanesulfonate as a serine proteinase inhibitor. II. In vivo effect on coagulofibrinolytic system in comparison with heparin or aprotinin.
    Ohno H; Kambayashi J; Chang SW; Kosaki G
    Thromb Res; 1981 Dec 1-15; 24(5-6):445-52. PubMed ID: 6178174
    [No Abstract]   [Full Text] [Related]  

  • 16. Antishock effect of gabexate mesilate (FOY).
    Oda T; Miyawaki T; Sameshima T; Miyao J; Arai Y; Yoshimine K; Yoshimura N
    Prog Clin Biol Res; 1983; 111():293-307. PubMed ID: 6408649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secretory responses of hypertrophied rat pancreas induced by repeated oral administrations of a synthetic protease inhibitor.
    Yonezawa H
    Jpn J Physiol; 1983; 33(2):183-95. PubMed ID: 6876500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimetastatic activity of a synthetic serine protease inhibitor, FOY-305 (Foypan).
    Ohkoshi M; Sasaki Y
    In Vivo; 2005; 19(1):133-6. PubMed ID: 15796165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes of aldolase and pyruvate kinase isoenzymes during liver cirrhosis induction with carbon tetrachloride and 2-acetylamino-fluorene.
    Gruszka S; Silber D; Checińska E; Rabczyński J; Kochman M
    Mater Med Pol; 1984; 16(2-4):75-80. PubMed ID: 6535051
    [No Abstract]   [Full Text] [Related]  

  • 20. Modelling of tumour--host coexistence In vitro in the presence of serine protease inhibitors.
    Engi H; Gyémánt N; Ohkoshi M; Amaral L; Molnár J
    In Vivo; 2009; 23(5):711-5. PubMed ID: 19779105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.